Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Internal research and development expenses Internal Research and Development Expenses [Member] Internal Research and Development Expenses Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Woodland, Texas Woodland, Texas [Member] Woodland, Texas Statistical Measurement Statistical Measurement [Domain] Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Document Fiscal Year Focus Document Fiscal Year Focus Adjustment to Compensation, Amount Adjustment to Compensation Amount Financial Instrument Financial Instrument [Axis] Segment Reporting [Abstract] Schedule of Investments Fair Value Measurement on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Common stock, $0.001 par value— 500,000,000 shares authorized as of May 31, 2026 and November 30, 2025; 103,701,511 and 101,807,484 shares issued and outstanding as of May 31, 2026 and November 30, 2025, respectively Common Stock, Value, Issued Accrued compensation Employee-related Liabilities, Current Regulatory milestone payments Revenue, Remaining Performance Obligation, Variable Consideration Amount, Regulatory Milestones Revenue, Remaining Performance Obligation, Variable Consideration Amount, Regulatory Milestones Restatement Determination Date Restatement Determination Date Maturities of marketable securities Proceeds from Sale, Maturity and Collection of Investments Contract assets Contract with Customer, Asset, after Allowance for Credit Loss Class of Warrant or Right Class of Warrant or Right [Domain] Number of warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Amendment Flag Amendment Flag Target licensing and reservation payments Revenue, Remaining Performance Obligation, Variable Consideration Amount, Target Licensing And Reservation Revenue, Remaining Performance Obligation, Variable Consideration Amount, Target Licensing And Reservation Current liabilities: Liabilities, Current [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Equity Distribution Agreement Equity Distribution Agreement [Member] Equity distribution agreement. Equity distribution agreement, commission percentage on gross sales price of shares Commission Percentage On Gross Sales Price Of Shares Commission percentage on gross sales price of shares. Unrealized loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Amortized cost, short-term Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current Other comprehensive loss, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Total Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross PEO Total Compensation Amount PEO Total Compensation Amount Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Number of RSUs, beginning balance (in shares) Number of RSUs, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Weighted-average number of shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Retirement Benefits [Abstract] Retirement Benefits [Abstract] Net accretion of discount on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Extension payment Proceeds From Collaboration Agreement, Extension Payment Proceeds From Collaboration Agreement, Extension Payment Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Performance obligation satisfied Contract with Customer, Performance Obligation Satisfied in Previous Period Interest and other income, net Interest and Other Income Entity Address, City or Town Entity Address, City or Town RSUs granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Software Software, Internally Developed and Purchased [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Term extension Collaboration Agreement Contract Term, Extension Collaboration Agreement Contract Term, Extension Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] RSUs vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Cash paid for amounts included in the measurement of lease liabilities: Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Drug targets Number Of Specified Drug Targets Number Of Specified Drug Targets Subsequent Event Type [Axis] Subsequent Event Type [Axis] Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of pre funded warrants Stock Issued During Period, Value, New Issues And Adjustments To Additional Paid In Capital, Warrant Issued Stock Issued During Period, Value, New Issues And Adjustments To Additional Paid In Capital, Warrant Issued Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Upfront payment of additional fees Upfront Payment Of Additional Fees Upfront payment of additional fees. Additions to property and equipment included in accounts payable and accrued expenses and other current liabilities Capital Expenditures Incurred but Not yet Paid Deferred revenue Increase (Decrease) in Contract with Customer, Liability Schedule of Segment Reporting Information Segment Reporting [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Related Party Related and Nonrelated Parties [Axis] Exercise price of warrants (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash provided by (used in) investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common Stock Equity [Text Block] Security Exchange Name Security Exchange Name Weighted-average exercise price, options granted (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Purchases of marketable securities Payments to Acquire Marketable Securities Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Operating lease liabilities, current Operating Lease, Liability, Current Greater than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Schedule of Property and Equipment Property, Plant, and Equipment [Table Text Block] Number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus NX-1607 NX-1607 [Member] NX-1607 Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Total liabilities Liabilities Trading Symbol Trading Symbol Expiration term Collaboration Agreement Expiration Term Collaboration Agreement Expiration Term Estimated fair value Debt Securities, Available-for-Sale, Excluding Accrued Interest Geographical [Domain] Geographical [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Total compensation cost related to stock-based awards yet to recognize Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Software in progress Software, In-Development [Member] Company Selected Measure Name Company Selected Measure Name Sale of Stock Sale of Stock [Domain] Transaction Transaction [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Unrealized loss on available-for-sale marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Supplemental disclosures of non-cash investing and financing activities: Noncash Investing and Financing Items [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Related Party Transactions [Abstract] Related Party Transactions [Abstract] Cash flows from operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Accrued expenses and other current liabilities Accrued Expenses And Other Liabilities Current Accrued expenses and other liabilities current. Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Weighted-average number of shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Clinical milestone payment Proceeds From Collaboration Agreement, Clinical Milestone Payment Proceeds From Collaboration Agreement, Clinical Milestone Payment Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Underlying Security Market Price Change Underlying Security Market Price Change, Percent U.S. treasury securities US Treasury Securities [Member] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Cash flows from operating leases Operating Lease, Payments Award Timing Predetermined Award Timing Predetermined [Flag] Total potential payment Collaborative Arrangement, Total Potential Payment Collaborative Arrangement, Total Potential Payment Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Schedule of Accrued Expenses and Other Current Liabilities Schedule Of Accrued Expenses And Other Current Liabilities Table [Table Text Block] Schedule of accrued expenses and other current liabilities. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Fair Value Debt Securities, Available-for-Sale [Abstract] Weighted-average grant date fair value, beginning balance (in USD per share) Weighted-average grant date fair value, ending balance (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value All Executive Categories All Executive Categories [Member] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Impairment loss Marketable Security, Realized Gain (Loss) Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Plan Name Plan Name [Domain] Antidilutive Securities Antidilutive Securities [Axis] Number of RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Weighted-average exercise price, beginning balance (in USD per share) Weighted-average exercise price, ending balance (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Healthcare Plan Provider Trust for Benefit of Employees [Member] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Renewal term Lessee, Operating Lease, Renewal Term Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Segment Information Segment Reporting [Text Block] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Class of Warrant or Right Class of Warrant or Right [Axis] Income Statement Location Location, Statement of Income, Balance [Axis] Gross Unrealized Loss Debt Securities, Available-for-Sale, Unrealized Loss Position [Abstract] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Area of office space leased Area Of Office Space Leased Area of office space leased. Issuance costs, common stock Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Proceeds from issuances of common stock in “at the market” financing, net of issuance costs Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Common stock, shares authorized (in shares) Common stock, shares authorized to issue (in shares) Common Stock, Shares Authorized Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization, consolidation and presentation of financial statements. Number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Exercise Price Award Exercise Price Cash flows from investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Related Party Transaction [Axis] Related Party Transaction [Axis] Segment Reporting [Line Items] Segment Reporting [Line Items] Document Quarterly Report Document Quarterly Report Weighted-average price per share (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Piper Sandler & Co. Piper Sandler And Co [Member] Piper Sandler & Co. Adoption Date Trading Arrangement Adoption Date Certain sales milestones payments Revenue, Remaining Performance Obligation, Variable Consideration Amount, Certain Sales Milestones Revenue, Remaining Performance Obligation, Variable Consideration Amount, Certain Sales Milestones Counterparty Name Counterparty Name [Domain] Total stockholdersʼ equity Beginning balance Ending balance Equity, Attributable to Parent Extended research term Contractual Extended Research Period Contractual extended research period. Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Operating lease, liability Operating Lease, Liability Insider Trading Policies and Procedures [Line Items] Options outstanding, beginning balance (in shares) Options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Condensed Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Security deposit Security Deposit Upfront cash payment Collaborative Arrangement, Upfront Payment Collaborative Arrangement, Upfront Payment Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Number of operating segments Number of Operating Segments Anti-dilutive securities excluded from computation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Restricted stock units issued and outstanding Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Schedule of Antidilutive Securities Excluded from Computation of Diluted Net Loss Per Share of Common Stock Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key Less: Accumulated depreciation and amortization Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Additional paid-in capital Additional Paid in Capital, Common Stock All Adjustments to Compensation All Adjustments to Compensation [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Income Statement [Abstract] Income Statement [Abstract] Stockholdersʼ equity: Equity, Attributable to Parent [Abstract] Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Document Transition Report Document Transition Report Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Total accrued expenses and other current liabilities Accrued And Other Liabilities Current Accrued and other liabilities current. Operating expenses: Operating Expenses [Abstract] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Laboratory equipment Laboratory Equipment [Member] Laboratory equipment. Number of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] City Area Code City Area Code Restricted stock units issued and outstanding Restricted Stock [Member] Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Subsequent Event Subsequent Events [Text Block] Amortization of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Reportable Segment Reportable Segment [Member] Reportable Segment Name Forgone Recovery, Individual Name Total compensation cost related to stock-based awards, recognition period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Statement [Line Items] Statement [Line Items] Total assets Assets Equity Incentive Plans Equity Incentive Plans [Member] Equity Incentive Plans Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Total common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Collaboration revenue Collaboration Revenue [Member] Collaboration Revenue Schedule of Stock-Based Compensation Expense Related to Stock Options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Proceeds from issuance of common stock under employee stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised Unrealized gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock in “at the market” financing, net of issuance costs (in shares) Issuance of common stock and pre-funded warrants, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Statement of Other Comprehensive Income [Abstract] Statement of Other Comprehensive Income [Abstract] Total stock-based compensation Share-Based Payment Arrangement, Expense Debt securities unrealized loss position, more than12 months number of positions Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Tenant improvements Tenant Improvements Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercise of stock options (in shares) Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Weighted-average grant date fair value, RSUs granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Collaboration revenue recognized from opening contract liability Contract with Customer, Liability, Revenue Recognized Subsequent Event Type [Domain] Subsequent Event Type [Domain] Accrued taxes Taxes Payable, Current Accumulated deficit Retained Earnings [Member] Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Total operating expenses Operating Expenses Money market funds Money Market Funds [Member] Weighted-average grant date fair value, RSUs forfeited (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Stock Plans and ESPP Stock Plans And Employee Stock Purchase Plan [Member] Stock plans and employee stock purchase plan. Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Options forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Net loss per share, diluted (in USD per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Sanofi Agreement Sanofi Agreement [Member] Sanofi agreement. Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Research and development Total research and development expenses Research and Development Expense Voting rights Common Stock, Voting Rights For Shareholders Common Stock, Voting Rights For Shareholders Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Schedule of Common Stock Shares Reserved for Future Issuance Schedule Of Common Stock Shares Reserved For Future Issuance Table [Table Text Block] Schedule of common stock shares reserved for future issuance. Research milestones payments received Research Milestones Payments Received Research milestones payments received. Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash flows from financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Total revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Total property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Maintenance costs and real estate taxes Variable Lease, Payment Issuance of Series D redeemable convertible preferred stock, per share (in USD per share) Shares Issued, Price Per Share Financial Instruments Financial Instruments [Domain] Roche Roche [Member] Roche Additional payments Additional Payments Additional Payments Pre Funded Warrants Pre-funded warrants issued and outstanding Pre Funded Warrants [Member] Pre funded warrants. Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Underlying Securities Award Underlying Securities Amount Issuance of common stock in “at the market” financing, net of issuance costs Stock Issued During Period, Value, New Issues Underwriters Over-Allotment Option [Member] Weighted-average exercise price, options forfeited (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price License revenue License Revenue [Member] License Revenue Segment Reporting [Table] Segment Reporting [Table] Shares available for grant under the stock plans (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Table] Computer equipment Computer Equipment [Member] Sale of Stock Sale of Stock [Axis] Schedule of Other Information Related to Leases Lease, Cost [Table Text Block] Chief Financial Officer Chief Financial Officer [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Loss from operations Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Related Party Transaction [Domain] Related Party Transaction [Domain] Pre Funded Warrants - 2022 Pre Funded Warrants - 2022 [Member] Pre Funded Warrants - 2022 Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Common stock, dividends declared (in USD per share) Common Stock, Dividends, Per Share, Declared Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Offering expenses Offering Cost, Expense Schedule of Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted- average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Products arising from collaboration Number Of Products Arising From Collaboration Number Of Products Arising From Collaboration Greater than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Equity Components Equity Components [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Class Of Stock [Line Items] Class of Stock [Line Items] Percentage of development cost Collaborative Arrangement, Percentage Of Development Cost Collaborative Arrangement, Percentage Of Development Cost Additional drug targets Number Of Additional Specified Drug Targets Number Of Additional Specified Drug Targets Entity Interactive Data Current Entity Interactive Data Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Contribution expense Defined Contribution Plan, Cost Entity Small Business Entity Small Business Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Termination Date Trading Arrangement Termination Date Brisbane, California Brisbane, California [Member] Brisbane, California Property, Plant, and Equipment [Line Items] Property, Plant, and Equipment [Line Items] Subsequent Events [Abstract] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other Other Liabilities, Current Other assets Other Assets, Noncurrent Document Type Document Type Variable consideration included in transaction price Variable Consideration Included In Transaction Price Variable consideration included in transaction price. Transfers Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Other Risks and Uncertainties Other Risks And Uncertainties [Policy Text Block] Other risks and uncertainties policy. Fair Value as of Grant Date Award Grant Date Fair Value Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest Schedule of Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Unrealized loss, short-term Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax, Current Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax, Current Reconciliation of cash, cash equivalents and restricted cash: Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation [Abstract] Zelebrudomide (NX-2127) Zelebrudomide (NX-2127) [Member] Zelebrudomide (NX-2127) Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Included in cash and cash equivalents Cash and Cash Equivalents [Member] Arrangement Duration Trading Arrangement Duration Subsequent Event [Line Items] Subsequent Event [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Gilead Agreement Gilead Agreement [Member] Gilead agreement. Less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Registered Direct Offerings Registered Direct Offerings [Member] Registered direct offerings. Remaining stock available for sale Sale Of Stock, Common Stock Remaining Available For Sale Sale Of Stock, Common Stock Remaining Available For Sale Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Commitments and contingencies (Note 6) Commitments and Contingencies Number of drug candidates Number Of Drug Candidates Number Of Drug Candidates Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Total property and equipment, gross Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Two Thousand Twenty Four Equity Inducement Plan Two Thousand Twenty Four Equity Inducement Plan [Member] Two Thousand Twenty Four Equity Inducement Plan Executive Category: Executive Category [Axis] Furniture and fixtures Furniture and Fixtures [Member] Counterparty Name Counterparty Name [Axis] Liabilities and stockholdersʼ equity Liabilities and Equity [Abstract] Other Commitments [Table] Other Commitments [Table] Award Type Award Type [Domain] Unrealized gain, short-term Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Current Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax, Current Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Transaction Type Transaction Type [Axis] PEO Name PEO Name Geographical [Axis] Geographical [Axis] Pre Funded Warrants - 2024 Pre Funded Warrants - 2024 [Member] Pre Funded Warrants - 2024 Leasehold improvements Leasehold Improvements [Member] Recorded deferred revenue Contract with Customer, Liability Cash and short-term investments Cash, Cash Equivalents, and Short-Term Investments Long-Lived Asset, Class Long-Lived Asset, Class [Axis] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Accrued clinical Accrued Clinical, Current Accrued Clinical, Current Other Commitments [Line Items] Other Commitments [Line Items] Weighted-average exercise price, options exercised (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Accrued professional services Accrued Professional Fees, Current Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accounts payable Increase (Decrease) in Accounts Payable Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Minimum common stock holding percentage Minimum Common Stock Holding Percentage Minimum common stock holding percentage. Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Subsequent Event [Table] Subsequent Event [Table] 2024 Public Offering Public Offering 2024 [Member] Public Offering 2024 Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization, consolidation and presentation of financial statements. Shares available for issuance under employee stock purchase plan Employee Stock Shares expected to be purchased under employee stock purchase plan Employee Stock [Member] Accrued contract research and lab supplies Accrued Contract Research And Lab Supplies Accrued contract research and lab supplies. Expenses related to the healthcare plan premiums Related Party Transaction, Amounts of Transaction Contractual initial research period Contractual Initial Research Period Contractual initial research period. Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Upfront payment Upfront Payment Upfront payment. Net loss per share, basic (in USD per share) Earnings Per Share, Basic Deferred revenue, current Contract with Customer, Liability, Current Total current assets Assets, Current Statistical Measurement Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Award Type Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss Accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Restricted cash Restricted cash Restricted Cash, Noncurrent Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common stock Common Stock [Member] Bexobrutideg (NX-5948) Bexobrutideg (NX-5948) [Member] Bexobrutideg (NX-5948) Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Organization Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Cover [Abstract] Cover [Abstract] Collaboration agreement contract term Collaboration Agreement Contract Term Collaboration agreement contract term. Equity Awards Adjustments Equity Awards Adjustments [Member] Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Total liabilities and stockholdersʼ equity Liabilities and Equity Options to purchase common stock issued and outstanding Employee Stock Option Options to purchase common stock issued and outstanding Share-Based Payment Arrangement, Option [Member] Segments [Axis] Segments [Axis] Pfizer Pfizer [Member] Pfizer Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Related Party Related and Nonrelated Parties [Domain] Plan Name Plan Name [Axis] Accrued interest receivable Interest Receivable, Current Tabular List, Table Tabular List [Table Text Block] Name Awards Close in Time to MNPI Disclosures, Individual Name Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] RSUs forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period General and administrative General and Administrative Expense Long-Lived Asset, Class Long-Lived Asset, Class [Domain] Sale price of stock (in USD per share) Sale of Stock, Price Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Schedule Of Property Plant And Equipment [Table] Property, Plant, and Equipment [Table] Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2026 and November 30, 2025; no shares issued and outstanding as of May 31, 2026 and November 30, 2025 Preferred Stock, Value, Issued Additional payment received to exercise option to expand number of targets Additional Payment Received To Exercise Option To Expand Number Of Targets Additional payment received to exercise option to expand number of targets. Adjustment to Compensation: Adjustment to Compensation [Axis] Accrued expenses and other current liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Marketable securities Estimated fair value, short-term Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Name Measure Name Income Taxes Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Research and development milestone payments Revenue, Remaining Performance Obligation, Variable Consideration Amount, Research And Development Milestones Revenue, Remaining Performance Obligation, Variable Consideration Amount, Research And Development Milestones Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional paid-in capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Total Debt Securities, Available-for-Sale, Unrealized Loss Position Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalent Operating lease expenses, excluding variable lease payments Operating Lease, Expense Company Selected Measure Amount Company Selected Measure Amount Warrants offering expenses Warrants Offering Expenses Warrants offering expenses. Number of performance obligations Number Of Performance Obligations Number Of Performance Obligations Entity Address, Address Line Two Entity Address, Address Line Two Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Current assets: Assets, Current [Abstract] Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Right-of-use assets recognized in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Weighted-average grant date fair value, RSUs vested (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Provision for (benefit from) income taxes Income Tax Expense (Benefit) Award Timing Method Award Timing Method [Text Block] Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Maximum increase or decrease percentage of warrants Maximum Increase Or Decrease Percentage Of Warrants Maximum increase or decrease percentage of warrants. Purchase price of warrants (in USD per share) Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights Class Of Warrant Or Right, Purchase Price Of Warrants Or Rights At the Market Offering At The Market Offerings [Member] At the market offerings. Net loss Net loss Net Income (Loss) Attributable to Parent Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Balance Sheet Location Location, Statement of Financial Position, Balance [Axis] Statement [Table] Statement [Table] Proceeds from issuance of warrants Proceeds from Issuance of Warrants Restatement Determination Date: Restatement Determination Date [Axis] Revenue recognized Contract With Customer Liability Revenue Recognized Excluding Opening Balance Contract With Customer Liability Revenue Recognized Excluding Opening Balance Proceeds from exercise of stock options Proceeds from Stock Options Exercised Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Gross Shares available for future equity grants Share-Based Payment Arrangement [Member] Defined Contribution Plan Defined Contribution Plan [Text Block] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block]